Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Tisagenlecleucelin tehokkuus- ja turvallisuustutkimus brasilialaispotilailla, joilla on akuutti lymfoblastinen leukemia tai diffuusi suuri B-soluinen lymfooma

maanantai 9. marraskuuta 2026 päivittänyt: Novartis Pharmaceuticals

Tisagenlecleucel-hoidon tehokkuus ja turvallisuus brasilialaispotilailla, joilla on akuutti lymfoblastinen leukemia tai diffuusi suuri B-solulymfooma: 15 vuoden mahdollinen rekisteritutkimus kahdella kohortilla

This will be a multicenter, national, non-interventional, prospective cohort study

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

Eligible participants will be pediatric (<18 years) and adult patients (aged 18 years or older) with B-cell malignancies who have received tisagenlecleucel through the commercial setting or out-of-specification (OOS) use in Brazil. We will collect data prospectively and complement missing information with retrospective data collection, when necessary. It is anticipated that approximately 200 patients will be enrolled in the cohort over 5 years divided among the study indications.

Since this is a non-interventional study, no administration of study drug or application of questionnaires will be mandated by this protocol. The study will consist of a "Pre-infusion" and a "Post infusion follow-up period" for up to 15 years post tisagenlecleucel infusion. All patients will be followed until death or last scheduled visit, whichever comes first.

For the study, "pre-infusion" and "follow-up post infusion" phases are defined as:

  • "Pre-infusion" will consist of the patient's information from the time of diagnosis untiljust prior to infusion with tisagenlecleucel.
  • "Follow-up Post infusion" information will comprise any information from the infusionof tisagenlecleucel onwards.

Opintotyyppi

Havainnollistava

Ilmoittautuminen (Arvioitu)

200

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Tutki yhteystietojen varmuuskopiointi

  • Nimi: Novartis Pharmaceuticals

Opiskelupaikat

      • São Paulo, Brasilia, 01509-010
        • Rekrytointi
        • Novartis Investigative Site
      • São Paulo, Brasilia, 01409-902
        • Rekrytointi
        • Novartis Investigative Site
    • Belo Horizonte
      • Minas Gerais, Belo Horizonte, Brasilia, 34006-059
        • Rekrytointi
        • Novartis Investigative Site
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasilia, 41253-190
        • Rekrytointi
        • Novartis Investigative Site
    • Paraná
      • Curitiba, Paraná, Brasilia, 81520-060
        • Rekrytointi
        • Novartis Investigative Site
    • São Paulo
      • São Paulo, São Paulo, Brasilia, 01323-900
        • Rekrytointi
        • Novartis Investigative Site
      • São Paulo, São Paulo, Brasilia, 04544-000
        • Rekrytointi
        • Novartis Investigative Site

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

1 sekunti - 100 vuotta (Lapsi, Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Näytteenottomenetelmä

Ei-todennäköisyysnäyte

Tutkimusväestö

The study population will include pediatric/ adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia aged 0-25 years and adult patients aged ≥ 18 years with relapsed/refractory Diffuse Large B-cell Lymphoma and relapsed/refractory follicular lymphoma, who received tisagenlecleucel infusion in the commercial setting or out-of-specification.

Kuvaus

Inclusion Criteria:

Patients eligible for inclusion in this study must meet the following criteria:

  1. Patients who receive tisagenlecleucel infusion in the commercial setting or out-of-specification (OOS) use, AND

  2. Signed informed consent must be obtained prior to participation in study, AND

    For ALL participants:

  3. Patients of any gender aged 0-17 years (named as pediatric) with relapsed/ refractory B-cell ALL diagnosis that received tisagenlecleucel infusion, OR

  4. Patients of any gender, aged 18-25 years (named as adults) - with relapsed/ refractory B-cell ALL diagnosis that received tisagenlecleucel infusion, OR

    For DBLCL and FL participants:

  5. Patients of any gender aged 18 years or older, who have been diagnosed with relapsed/ refractory Diffuse Large B-cell Lymphoma and received tisagenlecleucel infusion.

Exclusion Criteria:

  1. Patients who did not consent to data collection.
  2. Patients who received tisagenlecleucel infusion as part of any interventional clinical trial.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Havaintomallit: COHORT
  • Aikanäkymät: OTHER

Kohortit ja interventiot

Ryhmä/Kohortti
Interventio / Hoito
Acute Lymphoblastic Leukemia (ALL)

Children/young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia who received tisagenlecleucel infusion

Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study

Diffuse Large B-cell Lymphoma (DLBCL)

Adult patients with relapsed/refractory Diffuse Large B-cell Lymphoma who received tisagenlecleucel infusion

Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study

Follicular Lymphoma (FL)

Patients of any gender aged 18 year or older, with relapsed/refractory Follicular Lymphoma who received tisagenlecleucel infusion.

Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Overall response rate (ORR)
Aikaikkuna: Up to 15 years

The overall response rate will be defined as the total proportion of participants exhibiting either the best overall response (BOR) of complete or partial responses and the proportion of patient with BOR of CR/PR or CR/CRi for ALL patients will be reported along with its 95% CI.

For ALL participants, the BOR will be defined as a CR or a CRi in accordance with National Comprehensive Cancer Network (NCCN) guidelines and previous guidelines (Appelbaum et al 2007)(Cheson et al 2003).

For lymphomas, the BOR will be defined as a CR or PR in accordance with the Cheson response criteria (Cheson et al 2007) and the Lugano classification (Cheson et al 2016).

Up to 15 years
MRD negative overall response rate
Aikaikkuna: Up to 15 years

The percentage of B-cell ALL patients who achieve a Best Overall Response (BOR) of CR or CRi with a Minimal residual disease (MRD) negative bone marrow will be provided with 95% CI.

Up to 15 years
Duration of overall response (DOR)
Aikaikkuna: Up to 15 years

Duration of overall response (DOR) applies only to patients whose best overall disease response was either:

  • CR or PR for patients with lymphomas, or
  • CR or a CRi for patients with ALL.

DOR will be defined as the time from the date of first documented disease response (Complete Response (CR) or PR for patients with lymphomas, and Complete Remission (CR) or CRi for patients with ALL), whichever occurs first, to the date of first documented progression or first documented relapse according to indication, or to the date of death due to the underlying disease.

In case a patient does not have progression/relapse or death due to underlying disease (defined as the event for this outcome) prior to data cut-off, DOR will be censored at the date of the last assessment on or prior to the earliest censoring event.

Up to 15 years
Relapse-free survival (RFS)
Aikaikkuna: Up to 15 years

RFS is measured by the time from date of first documented disease response as CR or CRi to relapse or death due to any cause in ALL patients.

In case a patient does not have relapse or death due to any cause prior to data cutoff, RFS will be censored at the date of the last adequate assessment on or prior to the earliest censoring event.

Up to 15 years
Event-free survival (EFS) for ALL patients
Aikaikkuna: Up to 15 years

EFS is the time from date of first tisagenlecleucel infusion to treatment failure, relapse or death from any cause, whichever occurred first, for B-cell ALL patients.

Up to 15 years
Progression free survival (PFS) for DLBCL patients
Aikaikkuna: Up to 15 years

PFS is defined as the time from the date of first infusion to the date of event defined as the first documented progression of lymphoma or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of the last adequate assessment.

In case a patient does not have progression or death prior to data cutoff, PFS will be censored at the date of the last adequate assessment on or prior to the earliest censoring event.

Up to 15 years
Overall survival (OS)
Aikaikkuna: Up to 15 years

Overall survival is the time from date of first tisagenlecleucel infusion to the date of death due to any reason, In case a patient is alive at the date of last contact on or before data cutoff, OS is censored at the date of last contact.

Up to 15 years
Number of ALL patients with hematologic recovery
Aikaikkuna: Up to 15 years

Dates of hematological recovery (i.e., dates of Absolute Neutrophil Count (ANC) and platelet recovery) will be collected.

ANC recovery is defined as an ANC of ≥ 0.5 × 109/L (500/mm^3) for 3 consecutive laboratory values obtained on different days. Date of ANC recovery is the date of the first of 3 consecutive laboratory values where the ANC is ≥ 0.5 × 109/L (CIBMTR).

The first date of the 3 consecutive laboratory values obtained on different days where the platelet count was ≥ 20 × 109/L should be recorded. It should be ensured that no platelet transfusions were administered for 7 days immediately preceding this date (CIBMTR).

Up to 15 years

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
The type and frequency of SAEs and AE of special interest
Aikaikkuna: Up to 15 years

The type and frequency of SAEs and AE of special interest (including secondary malignancies) will be collected

Up to 15 years
Incidence and severity of CRS and ICANS among HTLV 1 and 2 positive versus HTLV 1 and 2 negative patients
Aikaikkuna: Up to 15 years

Incidence and severity of Cytokine release syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) among Human T-cell Lymphotropic Virus (HTLV) 1 and 2 positive versus HTLV 1 and 2 negative patients.

For CRS AE the protocol will follow the American Society of Transplant and Cellular Therapy (ASTCT) CRS Consensus Grading.

For ICANS AE the protocol will follow ASTCT consensus as well. Which establishes the Immune effector Cell-associated Encephalopathy (ICE Score) for adults/ adolescents and Cornell Assessment of Pediatric Delirium (CAPD) for pediatric patients under 12 years

Up to 15 years
Pregnancy rates
Aikaikkuna: Up to 15 years

Pregnancy rates will be collected

Up to 15 years
Number of patients with confirmed secondary malignancies diagnosis
Aikaikkuna: Up to 15 years

Number of patients with confirmed secondary malignancies diagnosis will be collected

Up to 15 years

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Tutkijat

  • Opintojohtaja: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Perjantai 24. marraskuuta 2023

Ensisijainen valmistuminen (Arvioitu)

Maanantai 23. marraskuuta 2037

Opintojen valmistuminen (Arvioitu)

Maanantai 23. marraskuuta 2037

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Tiistai 13. syyskuuta 2022

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Tiistai 13. syyskuuta 2022

Ensimmäinen Lähetetty (Todellinen)

Torstai 15. syyskuuta 2022

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 10. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 9. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa